Objective: To examine the impact of the government communicating uncertainties relating to COVID-19 vaccine effectiveness on vaccination intention and trust after people are exposed to conflicting information.
Design: Experimental design where participants were randomly allocated to one of two groups.
Setting: Online.
Participants: 328 adults from a UK research panel.
Intervention: Participants received either certain or uncertain communications from a government representative about COVID-19 vaccine effectiveness, before receiving conflicting information about effectiveness.
Main Outcome Measures: Vaccination intention and trust in government.
Results: Compared with those who received the uncertain announcement from the government, participants who received the certain announcement reported a greater loss of vaccination intention (d0.34, 95% CI (0.12 to 0.56), p=0.002) and trust (d0.34, 95% CI (0.12 to 0.56), p=0.002) after receiving conflicting information.
Conclusions: Communicating with certainty about COVID-19 vaccines reduces vaccination intention and trust if conflicting information arises, whereas communicating uncertainties can protect people from the negative impact of exposure to conflicting information. There are likely to be other factors affecting vaccine intentions, which we do not account for in this study.
Trial Registration Number: Open Science Framework: https://osf.io/c73px/.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453426 | PMC |
http://dx.doi.org/10.1136/bmjopen-2021-051352 | DOI Listing |
Neurooncol Adv
November 2024
Huntsman Cancer Institute, Salt Lake City, UT, USA.
Background: Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance.
View Article and Find Full Text PDFMed Decis Making
December 2024
Department of Social & Behavioral Sciences, College of Public Health, Temple University, Philadelphia, PA, USA.
Background: In the United States, human papillomavirus (HPV) vaccination among 27- to 45-y-olds (mid-adults) is recommended based on shared clinical decision making with a health care provider. We developed a patient decision aid tool to support the implementation of this mid-adult HPV vaccination guideline. The purpose of this study was to evaluate the effect of a patient decision aid tool for HPV vaccination, HPV DECIDE, compared with an information fact sheet among mid-adults who have not received the HPV vaccine.
View Article and Find Full Text PDFDisaster Med Public Health Prep
December 2024
College of Population Health, University of New Mexico, Albuquerque, NM, USA.
Objective: To estimate COVID-19 vaccine intention, uptake, and hesitancy among essential workers.
Methods: A cross-sectional survey of USDA-certified organic producers. An electronic survey was used for data collection.
Health Commun
December 2024
Brian Lamb School of Communication, Purdue University.
This study examines the factors shaping individuals' reactions to health-protective norm violations through the lens of cognitive accessibility, the risk-as-feelings hypothesis, and the tripartite decision-making framework. By surveying 1,426 U.S.
View Article and Find Full Text PDFPLOS Glob Public Health
December 2024
Research Unit Public Health: From Biostatistics to Health Promotion, University of Liège, Liège, Belgium.
Even before the COVID-19 pandemic, vaccine hesitancy was one of the main global public health threats. Unfortunately, the COVID-19 crisis and its associated risks only reinforced this hesitancy. This study aimed to identify to what extent the COVID-19 vaccination affected confusion around vaccination in general, its change and any associated factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!